comparemela.com

Latest Breaking News On - Johnw osborn - Page 2 : comparemela.com

BioSig s Division NeuroClear Technologies Signs a Research Agreement with the University of Minnesota

BioSig’s Division NeuroClear Technologies Signs a Research Agreement with the University of Minnesota BioSig’s Division NeuroClear Technologies Signs a Research Agreement with the University of Minnesota Westport, CT, Dec. 18, 2020 BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company and its NeuroClear Technologies division signed a new research agreement with the University of Minnesota.  Under the terms of the agreement, the Company intends to launch a program to develop novel therapies to treat sympathetic nervous system disease. Due to launch in Q4 2020, the program studies are expected to form a foundation for developing a new platform technology to address disorders of the autonomic nervous system. NeuroClear intends to

BioSig s Division NeuroClear Technologies Signs a Research Agreement with the University of

Press release content from Globe Newswire. The AP news staff was not involved in its creation. BioSig’s Division NeuroClear Technologies Signs a Research Agreement with the University of . BioSig Technologies, Inc.December 18, 2020 GMT Westport, CT, Dec. 18, 2020 (GLOBE NEWSWIRE) BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company and its NeuroClear Technologies division signed a new research agreement with the University of Minnesota.  Under the terms of the agreement, the Company intends to launch a program to develop novel therapies to treat sympathetic nervous system disease. Due to launch in Q4 2020, the program studies are expected to form a foundation for developing a new platform technology to address disorders of the

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.